- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03426098
Secret Micro-Needle Fractional RF System® for the Treatment of Facial Wrinkles
A Prospective, Single-center, Investigator-blinded Trial to Evaluate the Safety and Efficacy of Secret Micro-Needle Fractional RF System® for the Treatment of Facial Wrinkles
Study Overview
Detailed Description
Subjects satisfying all inclusion and exclusion criteria will be enrolled in this trial. After baseline evaluation, all subjects will undergo a series of 3 facial treatments with the Secret Micro-Needle Fractional RF System® at 4 week intervals.
Blinded-investigator and subject self-assessments will be performed at Baseline and Days 28, 56, 146, and 180 to evaluate treatment efficacy for facial wrinkling. Of note, the blinded-investigators will be blinded to treatment settings and technique, and number of treatments. Safety will be evaluated by subject diaries, as well as investigator- and subject-rated evaluations of adverse events at all follow-up visits. Mandatory standard 2D digital photography, Canfield VISIA and VECTRA 3D digital photography will be performed at baseline and at each office visit.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
San Diego, California, United States, 92121
- West Dermatology Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males or females in good general health who are greater than 22 years of age.
- Subjects may be of Fitzpatrick Skin Types I through VI.
- Subjects must desire improvement of facial skin texture and wrinkling.
- Subjects must have at least a score of 2 on the Fitzpatrick Wrinkle Scale evaluating the forehead, cheeks, and periorbital areas and Modified Fitzpatrick Wrinkle Scale evaluating the nasolabial folds (Appendix A1 and A2).
- Subjects must be willing to provide written informed consent, HIPAA authorization, and photographic release.
- Subjects must be willing to follow study instructions and complete all required visits.
- Negative urine pregnancy test results at the time of study entry (if applicable).
- The subject is healthy as judged by medical history and investigator's assessment of current health
- Female subjects will be either of non-childbearing potential defined as:
1. Having no uterus. 2. No menses for at least 12 months. Or; (WOCBP) women of childbearing potential must agree to use an effective method of birth control during the course of the study, such as:
- Oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine device (systemic birth control must have been started 30 days or more prior to enrolling)
- Intrauterine coil
- Bilateral tubal ligation
- Barrier method used with an additional form of contraception (e.g., sponge, spermicide or condom)
- Abstinence (If practicing abstinence must agree to use barrier method described above (4) if becomes sexually active).
- Vasectomized partner (Must agree to use barrier method described above (4) if becomes sexually active with non-vasectomized).
Exclusion Criteria:
- A subject who has undergone treatment with any non-ablative laser, including IPL, within the last 3 months and any ablative laser within the last 6 months.
- A subject who has undergone any microneedling treatment within the last 3 months
- A subject with a history of previous fat transfer, injectable calcium hydroxylapatite or poly-l-lactic acid to the study area within the past 6 months.
- A subject with a history of injection of hyaluronic acid dermal fillers in the study area within the past six months.
- Retinoid, hydroquinone, microdermabrasion, or chemical peel treatments to the face within one month prior to study participation or during the study.
- Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research studies.
- Presence of an active systemic or local skin disease that may affect wound healing.
- Presence of scarring, sunburn, tattoos, open wounds or other skin condition in area to be treated that would interfere with the assessments of this study.
- Individuals who have current skin cancers or suspicious lesions in the treatment area per Investigator.
- Individuals who are nursing, pregnant, or planning to become pregnant during the study.
- Patients who have a history with keloid formation or hypertrophic scarring.
- Inability to understand the protocol or to give informed consent.
- Subjects with deep dermal scarring or thick sebaceous skin of the treatment area.
- History of impaired immune system, including but not limited to HIV, current malignancy.
- History of chronic drug or alcohol abuse.
- Current smoker or history of smoking in the last one year.
- Subjects with known bleeding disorder or is receiving medication that will likely increase the risk of bleeding as the result of injection per investigator discretion.
- Concurrent therapy that, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study device.
- Subjects who anticipate the need for surgery or overnight hospitalization during the study.
- Subjects who, in the investigator's opinion, have a history of poor cooperation, noncompliance with medical treatment, or unreliability.
History of using the following prescription medications:
- Current use of psychiatric drugs that in the investigators opinion would impair the subject from understanding the protocol requirements or understanding and signing the informed consent.
- Immunosuppressive medications.
- Subjects with implantable cardiac devices, such as pacemakers or implantable cardioverter-defibrillators.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment
After baseline evaluation, all subjects will undergo a series of 3 facial treatments with the Secret Micro-Needle Fractional RF System® at 4 week intervals.
|
A series of 3 facial treatments with the Secret Micro-Needle Fractional RF System® at 4 week intervals.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Wrinkles
Time Frame: Baseline to Day 146
|
Improvement in Wrinkles Based on the Fitzpatrick Wrinkle Scale
|
Baseline to Day 146
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rating of Non-Sequential Images
Time Frame: Baseline, Day 28, and Day 56.
|
Ratings of non-sequential images of subjects at baseline, Day 28, and Day 56.
Improvement is defined as a minimum improvement by a score of 1 on the Fitzpatrick Wrinkle Scale or Modified Fitzpatrick Wrinkle Scale as graded by two out of three blinded evaluators, who will be blinded to treatment settings and technique, and number of treatments
|
Baseline, Day 28, and Day 56.
|
Global Aesthetic Improvement Score
Time Frame: Baseline to Day 28, 56, and 146
|
Investigator Assessed Global Aesthetic Improvement Score
|
Baseline to Day 28, 56, and 146
|
Subject Satisfaction
Time Frame: Baseline to Day 28, 56, and 146
|
Subject-assessed Satisfaction with Facial Appearance scale (FACE-Q)
|
Baseline to Day 28, 56, and 146
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Mitchel P Goldman, MD, Cosmetic Laser Dermatology and West Dermatology Research
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 0922-1228
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aging
-
Tuba MadenCompletedAging | Aging Problems | Aging Disorder
-
Radboud University Medical CenterNot yet recruitingAging | Aging Well | Immuno Aging
-
University of Santiago de CompostelaEuropean Regional Development Fund; Center for Industrial Technological Development...Completed
-
TruDiagnosticBlushield USANot yet recruitingAging | Aging Well
-
San Diego State UniversityCompleted
-
Lithuanian Sports UniversityCompletedAging | Healthy AgingLithuania
-
Amazentis SAproDERM GmbHCompleted
-
University of West AtticaNot yet recruiting
-
University of Santiago de CompostelaAgencia Estatal de Investigación, SpainRecruiting
-
Beijing HospitalBGI-ShenzhenCompletedAging | Healthy Aging
Clinical Trials on Secret RF
-
Cutera Inc.Completed
-
London School of Hygiene and Tropical MedicineCentre for Infectious Disease Research in ZambiaCompleted
-
Klein Buendel, Inc.Pennington Biomedical Research CenterCompletedSleep Deprivation | Overweight and Obesity | Health BehaviorUnited States
-
Home Skinovations Ltd.CompletedGingivitis | Plaque | Calculus, DentalUnited States
-
GiMer MedicalCompletedLow Back Pain | Chronic Pain | Lower Limb PainTaiwan
-
Venclose, Inc.CompletedChronic Venous InsufficiencyGermany
-
Syneron MedicalCompletedSkin Resurfacing | Wrinkle ReductionUnited States, Canada
-
BTL Industries Ltd.CompletedCircumferential Reduction | Waist Circumferential Reduction
-
BTL Industries Ltd.CompletedPeriorbital Wrinkles
-
Home Skinovations Ltd.Completed